ArticleRNA (New York, N.Y.)2009
Cordycepin interferes with 3' end formation in yeast independently of its potential to terminate RNA chain elongation.
Article in RNA (New York, N.Y.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- A Systematic Review of the Biological Effects of Cordycepin.Molecules (Basel, Switzerland) · 2021Pooled it
- Research advances on Cordyceps sinensis and its components in relation to omics biomarkers for the neurological disorders.Die Naturwissenschaften · 2026Review
- Cordycepin and Its Structural Derivatives Effectively Suppress the High Expression of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase in Breast Carcinomas: A Computational Drug Development Approach.Current medicinal chemistry · 2025Article
- EngineeringSynthetic and systems biotechnology · 2023Article
- Protective effects of cordycepin pretreatment against liver ischemia/reperfusion injury in mice.Immunity, inflammation and disease · 2023Article
- Exploring the Bioactive Mycocompounds (Fungal Compounds) of Selected Medicinal Mushrooms and Their Potentials against HPV Infection and Associated Cancer in Humans.Life (Basel, Switzerland) · 2023Review
- Synthesis and Characterization of NUC-7738, an Aryloxy Phosphoramidate of 3'-Deoxyadenosine, as a Potential Anticancer Agent.Journal of medicinal chemistry · 2022Article
- Chinese Cordyceps: Bioactive Components, Antitumor Effects and Underlying Mechanism-A Review.Molecules (Basel, Switzerland) · 2022Review
- Genomic Comparative Analysis ofMetabolites · 2022Article
- Cordycepin: a bioactive metabolite of CJournal of biomolecular structure & dynamics · 2022Article
- Cordycepin Inhibits the Growth of Hepatocellular Carcinoma by Regulating the Pathway of Aerobic Glycolysis.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Genetic and pharmacological evidence for kinetic competition between alternative poly(A) sites in yeast.eLife · 2021Article
- Transcriptomic Responses ofFrontiers in nutrition · 2021Article
- Enhanced production of cordycepin inBiotechnology reports (Amsterdam, Netherlands) · 2020Article
- The kinase Isr1 negatively regulates hexosamine biosynthesis in S. cerevisiae.PLoS genetics · 2020Article
- Mechanism of Activation of AMPK by Cordycepin.Cell chemical biology · 2020Article
- Therapeutic Potential and Biological Applications of Cordycepin and Metabolic Mechanisms in Cordycepin-Producing Fungi.Molecules (Basel, Switzerland) · 2019Review
- Se-EnrichedOncoTargets and therapy · 2019Article
- Cordycepin Induces Apoptosis and G2/M Phase Arrest through the ERK Pathways in Esophageal Cancer Cells.Journal of Cancer · 2019Article
- The Anticancer Properties of Cordycepin and Their Underlying Mechanisms.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cordycepin (3' deoxyadenosine) is a biologically active compound that, when incorporated during RNA synthesis in vitro, provokes chain termination due to the absence of a 3' hydroxyl moiety. We were interested in the effects mediated by this drug in vivo and analyzed its impact on RNA metabolism of yeast. Our results support the view that cordycepin-triphosphate (CoTP) is the toxic component that is limiting cell growth through inhibition of RNA synthesis. Unexpectedly, cordycepin treatment modulated 3' end heterogeneity of ACT1 and ASC1 mRNAs and rapidly induced extended transcripts derived from CYH2 and NEL025c loci. Moreover, cordycepin ameliorated the growth defects of poly(A) polymerase mutants and the pap1-1 mutation neutralized the effects of the drug on gene expression. Our observations are consistent with an epistatic relationship between poly(A) polymerase function and cordycepin action and suggest that a major mode of cordycepin activity reduces 3' end formation efficiency independently of its potential to terminate RNA chain elongation. Finally, chemical-genetic profiling revealed genome-wide pathways linked to cordycepin activity and identified novel genes involved in poly(A) homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.